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Background: Interstitial tonicity increases vascular endothelial growth factor-C
(VEGF-C), a lymphangiogenic factor in salt-induced hypertension. Therefore, it can
be assumed that changes of serum VEGF-C level may be associated with increasing
blood pressure. However, there is no report about the changes of serum VEGF-C
levels in patients with chronic kidney disease (CKD). The aims of this study were to
investigate the changes of serum and urine VEGF-C levels in patients with CKD stage
3–4 and to evaluate the relationship between blood pressure and serum VEGF-C
levels in the patients with CKD stage 5 and hemodialysis.
Methods: Glomerular ﬁltration rate (GFR) was assessed by the Modiﬁcation of Diet
in Renal Disease equation. Blood pressure and VEGF-C levels (serum and urine)
were measured by enzyme-linked immunosorbent assay (ELISA) in nine patients
with stage 3–4 CKD, 41 hemodialysis patients, and eight healthy individuals.
Results: The median serum level of VEGF-C in patients with stage 3–4 CKD and
stage 5 hemodialysis signiﬁcantly decreased in comparison with healthy indivi-
duals. Urinary VEGF-C excretion increased in patients with stage 3–4 CKD compared
with healthy control patients. For 41 hemodialysis patients, the serum level of
VEGF-C in patients with stage 1 or stage 2 hypertension with hemodialysis did not
signiﬁcantly increase when compared with prehypertension hemodialysis patients.
Conclusion: We demonstrated that circulating levels of VEGF-C were decreased in
patients with CKD, and the decrease of VEGF-C in patients with stage 3–4 CKD
coincided with an increase in the urinary excretion of VEGF-C.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license




Vascular endothelial growth factor (VEGF) is a key molecule
for angiogenesis and lymphangiogenesis [1]. The VEGF families
are composed of six different proteins: VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E, and placental growth factor. The VEGF binds
three highly related receptor tyrosine kinases (RTKs), VEGFR-1,
VEGFR-2, and VEGFR-3. One of the members of the VEGF family,shed by Elsevier. This is an open access article under the CC BY-NC-ND
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VEGF-C has high afﬁnity for both VEGFR-2 and VEGFR-3 [2]. The
VEGF-C through VEGFR-2 or VEGFR-3 has a critical role in
mitogenesis, migration, and survival of lymphatic endothelial
cells [3].
Recently, it was suggested that the mononuclear phagocyte
system is involved in the control of interstitial volume and blood
pressure(BP) homeostasis. High salt diet feeding activates the
tonicity-responsive enhancer binding protein (TonEBP) in mono-
nuclear phagocyte cells that are present in the skin [4,5]. Activa-
tion of TonEBP increases VEGF-C production and increases
lymphangiogenesis [6,7]. Thus, VEGF-C can be linked to maintain
a normal blood pressure by regulating interstitial sodium accu-
mulation state. Dysregulation of this physiological extra renal
mechanism may lead to salt-sensitive hypertension [4,5].
VEGF inhibitors such as bevacizumab [8], sunitinib [9],
sorafenib [10], vatalanib [11], and cediranib [12] have been
used in the treatment of patients with tumor metastasis and
mass growth in lung, colorectal, and skin cancer. The adverse
effect of these antiangiogenesis therapies has been demon-
strated. Patients with metastatic renal cell carcinoma treated
with inhibitor of VEGF have high incidence of intracerebral
hemorrhage due to uncontrolled hypertension [13]. The
mechanisms of hypertension induced by angiogenic inhibitor
are related to an increase of systemic vascular resistance as a
result of vascular rarefaction, dysregulation of renal endothe-
lial cells, and podocyte VEGF expression [13]. Therefore,
inhibition of VEGFR axis may increase BP in cancer patients.
It was demonstrated that VEGF-C levels were higher in
patients with preeclampsia than those with gestational hyper-
tension [14], and VEGF-C has a role in salt homeostasis in
humans [15]. These results suggest that changes of VEGF-C
expression may be associated with hypertension.
However, there is currently no report about the changes of
serum VEGF-C levels in patients with chronic kidney disease
(CKD) and the relationship between the degree of hyperten-
sion and serum VEGF-C level in these patients. We assumed
that the changes of serum VEGF-C level in patients with CKD
may be associated with increases in BP, and there is a relation-
ship between degree of hypertension and serum VEGF-C level.
The aims of this study were to investigate the changes of
serum and urine level of VEGF-C levels in patients with CKD
stage 3–4 and to evaluate the relationship between BP and
serum VEGF-C levels in the patients with CKD stage 5 and
hemodialysis.Methods
Study populations
The Chonbuk National University Hospital Ethical Commit-
tee approved the protocol. For analyses of serum and urine
levels of VEGF-C between healthy patients and predialysis
CKD stage 3–4 and CKD stage 5 hemodialysis (HD) patients, we
enrolled eight healthy control patients, nine patients with CKD
stage 3–4, and 41 patients with CKD stage 5 and HD. For
analysis, correlation between circulating VEGF-C levels and
blood pressure stage in HD patients, we grouped the HD
patients as seven with prehypertension, 17 with stage 1 hyper-
tension, and 17 with stage 2 hypertension.
The serum and urine for this study were provided by the
Biobank of Chonbuk National University Hospital, and allsamples derived from the National Biobank of Korea were
obtained with informed consent under institutional review
board-approved protocols. The patients with CKD stage 3–4
had a stable serum creatinine level within 10% for at least
6 months prior to inclusion. Exclusion criteria for the CKD
study population were previous transplantation, medication
with Oriental medicine, extremities amputation, or acute
inﬂammation. Patients with CKD stage 3 or 4 were deﬁned
by the Modiﬁcation of Diet in Renal Disease (MDRD) estimated
glomerular ﬁltration rate (eGFR) between 30–59 mL/min/
1.73 m2 and 15–29 mL/min/1.73 m2, respectively. The dialysis
patients had maintained hemodialysis three times a week and
no medical events in the 6 months prior to inclusion in this
study. The number of anuric HD patients was 38. In all of these
patients, a detailed history and laboratory examination data
were extracted by electronic medical records. Eight healthy
patients were included as control patients. Edema was deﬁned
by depressing the skin with a ﬁnger by applying pressure to
the pretibial area. Cerebrovascular disease included cardiovas-
cular events such as myocardial infarction and/or revascular-
ization procedures, stroke, new-onset or worsening congestive
heart failure, and peripheral arterial disease.
BP measurement
BP was measured oscillometrically in the supine position in a
quiet environment with an automated device (Dinamap, Critikon
Co., Tampa, FL, USA) in healthy control patients and those with
CKD stages 3 and 4. The mean of three consecutive measure-
ments, taken 5 minutes apart after a rest of at least 20 minutes,
was taken for analysis. In the HD patients, BP was assessed
noninvasively (Phoenix Hemodialysis System, Gambro, Lund,
Sweden) prior to and after hemodialysis in the supine position.
We also measured BP every hour during hemodialysis. Mean
value of at least four measurements was used for analysis. The
patients were classiﬁed as having prehypertension (BP 120–139/
80–89 mmHg), stage 1 hypertension (BP 140-159/90–99 mmHg),
and stage 2 hypertension (BP ≥ 160/100 mmHg) [16].
Antihypertensive medication
Antihypertensive medication was evaluated by electrical med-
ical records. Medication was quantiﬁed using the Anatomical
Therapeutic Chemical (ATC) classiﬁcation system. According to
theWorld Health Organization recommendation, the deﬁned daily
dose was used as a measuring unit [17].
Blood VEGF-C measurement
After 2 hours of hemodialysis, blood samples for measure-
ment of VEGF–C were drawn with the patient in a supine
position. The serum level of VEGF-C was measured by enzyme-
linked immunosorbent assay (ELISA) according to the manu-
facturer's guidelines (eBioscience, San Diego, CA, USA).
Measurement of urinary VEGF–C
VEGF–C urine levels were measured simultaneously with blood
levels. The urine level of VEGF-C wasmeasured by ELISA according
to the manufacturer's guidelines (eBioscience). Urine VEGF-C (pg)
per urine creatinine (mg) was calculated by the urine level of
VEGF-C (pg/mL) divided by urine creatinine (mg/dL).
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Fractional excretion (FE) of VEGF-C is the percentage of the
VEGF-C ﬁltered by the kidney that is excreted in the urine. This
formula is represented mathematically as:
FEVEGF–C ð%Þ ¼ 100
Urine VEGF–C Serum creatinine
Serum VEGF–C Urine creatinine
Biochemical parameters
All measures were taken at the same clinical visit; prior to a
midweek session of HD or at clinic review for patients with CKD
stage 3–4. Serum and urine creatinine and serum cholesterol
were measured using a Hitachi 7180 autoanalyzer (Hitachi High-
Technologies Corporation, Tokyo, Japan). Serum samples from
patients with hemodialysis were taken prehemodialysis.
Statistical analyses
Data are presented as median (25–75 percentiles) or as
mean 7 standard deviation (SD). Normality tests and other
analyses were performed using the SPSS version 17.0 (SPSS
Inc., Chicago, IL, USA). The stage 3–4 CKD subgroups, HD
patients, and the healthy control patients were analyzed using
the Student t test. The Chi-square test (or Fisher's exact test)
was used for comparing categorical variables. Nonparametric
Mann-Whitney U tests were used for non-normally distributed
variables (VEGF-C levels, urine VEGF-C/urine creatinine ratio,Table 1. Baseline characteristics of healthy control subjects, chronic kid
Parameters Controls (
Age (y) 31.3 7
Sex (male/female) 6/2
Smokers (n, %) 3 (37
SBP (mmHg) 122.5 7
DBP (mmHg) 76.2 7
Serum Cr (mg/dL) 0.8 7
eGFR (mL/min/1.73m2) 107.1 7
Total cholesterol (mg/dL) 187.5 7
Diabetes mellitus (n, %) 0 (0
Cerebrovascular disease (n, %) 0 (0
Cancer (n, %) 0 (0
Diuretic (n, %) 0 (0
Edema (n, %) 0 (0
No. of patients with antihypertensive drug (n, %) 0 (0
a P o 0.01 versus control subjects.
b P o 0.05 versus control subjects.
CKD, chronic kidney disease; Cr, creatinine; CVA, cerebrovascular accident;
by the Modiﬁcation of Diet in Renal Disease equation; HD, hemodialysis; SB
Table 2. The number of concomitant total antihypertensive drugs (The
Antihypertensive drugs CKD stage 3–4 (n
Calcium antagonist 9 (1.00)
β-blocker 1 (0.11)
α-blocker 0 (0)
α- and β-blocker 4 (0.44)




ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker.and FE of VEGF-C). The degree of clinical correlation was
estimated by variable Pearson method. Statistical signiﬁcance
was accepted at a two-sided P value of o 0.05.Results
Patient demographics
The clinical characteristics of the study participants are
described in Table 1. The mean age of control patients was
signiﬁcantly lower than those of patients with CKD stage 3–4
and HD patients (31.3 7 6.7 years in healthy control patients, 62.2
7 14.4 years in patients with CKD stage 3–4 CKD, and 61.3 7 13.3
years in HD patients; P o 0.01). The BPs and serum creatinine
levels were signiﬁcantly higher in patients with CKD stage 3–4
and HD patients compared with normal control patients (BP 141.8
7 14.4/78.8 7 14.5 mmHg in patients with CKD stage 3–4, 152.8
7 12.3/83.1 7 10.1 mmHg in HD patients, and 122.5 7 8.1/76.2
7 6.4 mmHg in healthy control patients, P o 0.01; mean serum
creatinine level, 3.98 7 2.06 mg/dL in patients with CKD stage 3–
4, 7.37 7 2.80 mg/dL in HD patients, and 0.82 7 0.20 mg/dL in
healthy control patients, P o 0.001). The mean eGFR was 16.1 7
8.2 mL/min/1.73m2 in patients with CKD stage 3–4, 5.9 7 1.9 mL/
min/1.73m2 in HD patients, and 107.1 7 22.4 mL/min/1.73m2 in
healthy control patients (P o 0.01). There were no statistically
signiﬁcant differences in male-to-female ratio (2/7 in patients with
CKD stage 3–4, 19/22 in HD patients, and 6/2 in healthy control
patients) and percentage of smokers (3/9 in patients with CKD
stage 3–4, 21/41 in HD patients, and 6/2 in healthy controlney disease stage 3–4 and hemodialysis patients
n ¼ 8) CKD stage 3–4
(n ¼ 9)
CKD stage 5 with
HD (n ¼41)
6.7 62.2 7 14.4a 61.3 7 13.3a
2/7 19/22
.5) 3 (33.3) 21 (51.2)
8.1 141.8 7 14.4a 152.8 7 12.3a
6.4 78.8 7 14.5 83.1 7 10.1b
0.2 3.9 7 2.1a 7.4 7 2.8a
22.4 16.1 7 8.2a 5.9 7 1.9a
37.8 181.4 7 64.1 198.3 7 56.9
) 2 (22.2) 11(26.8)
) 1 (11.1) 8 (19.5)
) 0 (0) 8 (19.5)
) 4 (44.4) 7 (17.0)
) 2 (22.2) 4 (9.7)
) 9 (100)* 38 (92.6)a
DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate
P, systolic blood pressure.
number of antihypertensive drugs/person)







Table 3. The median serum levels of vascular endothelial growth factor-C in chronic kidney disease stage 3–4, hemodialysis patients, and
healthy controls
Parameters Controls (n ¼ 8) CKD stage 3–4 (n ¼ 9) CKD stage 5 with HD (n ¼ 41)
Serum VEGF-C (pg/ml) 2341.1 (1679.1–7952.1) 114.6a (49.0–353.1) 146.4a (98.6–245.8)
a P o 0.05 versus control subjects.
CKD, chronic kidney disease; VEGF-C, vascular endothelial growth factor-C.
Figure 1. Urinary excretions of VEGF-C in patients with CKD stage 3–4 (CKD stages 3 and 4) and healthy control subjects (Control). (A) Urine
levels of VEGF-C per urine creatinine in patients with CKD stage 3–4 and healthy control subjects. (B) Fractional excretion of VEGF-C in patients with
CKD stage 3–4 and healthy control subjects. *P o 0.05 versus control. CKD, chronic kidney disease; VEGF-C, vascular endothelial growth factor.
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difference in mean total cholesterol level between the CKD groups
and control patients (181.4 7 64.1 mg/dL for patients with CKD
stage 3–4, 198.3 7 56.9 mg/dL for HD patients, and 187.5 7
37.8 mg/dL for healthy control patients). Antihypertensive drugs
weremore frequently used in patients with CKD stage 3–4 and HD
patients than healthy control patients (Table 2).Decreased serum VEGF-C levels in patients with
CKD stage 3–4
As shown in Table 3, median serum VEGF-C levels decreased
in patients with CKD stage 3–4 compared with healthy control
patients [114.6 (49.0–353.1) vs. 2341.1 (1679.1–7952.1) pg/mL;
P o 0.05]. Median serum VEGF-C levels of the HD patients were
also decreased in comparison with healthy control patients [146.4
(98.6–245.8) vs. 2341.1 (1679.1–7952.1) pg/mL; P o 0.05].Increased urinary excretion of VEGF-C in patients with CKD
stage 3–4
To evaluate whether urinary VEGF-C excretion was
increased, we measured urine VEGF-C per urine creatinine
and FE of VEGF-C in patients with CKD stage 3–4. The urine
VEGF-C (pg) per urine creatinine (mg) were signiﬁcantly
increased in patients with CKD stage 3–4 compared with
healthy control patients [40.1 (27.7–44.1) ng of urine VEGF-C
per mg of urine creatinine to healthy control patients, 156.4
(82.0–283.0) ng of urine VEGF-C per mg of urine creatinine in
patients with CKD stage 3–4; P o 0.01] (Fig. 1A). The FE of
VEGF-C was also increased in patients with CKD stage 3–4
compared with healthy control patients [3.53 (1.60–14.11)% in
patients with CKD stage 3–4 and 0.01 (0.00–0.03)% in healthy
control patients; P o 0.01] (Fig. 1B). These data suggested that
urinary excretion of VEGF-C was increased in patients with
CKD stage 3–4.No relationship between serum VEGF-C and degree of
hypertension
The concentrations of serum VEGF-C in patients with stage 1
hypertension or stage 2 hypertension tended to be higher than
those in healthy control patients, but the differences did not reach
statistical signiﬁcance (536.5 7 982.2 pg/mL to stage 1 hyperten-
sion; 386.8 7 991.4 pg/mL to stage 2 hypertension, and 116.2 7
30.6 pg/mL prehypertension; P 4 0.05). Thus, our data showed
that no signiﬁcant differences in the serum concentrations of
VEGF-C were detected between prehypertension, stage 1 hyper-
tension, and stage 2 hypertension group in HD patients. We also
evaluated the correlation between serum levels of VEGF-C and the
number of antihypertensive drugs in HD patients. Our data
showed that calcium antagonists were more frequently used with
concomitant drugs in patients with stage 1 and stage 2 hyper-
tension than in healthy control patients. However, other antihy-
pertensive concomitant drugs were similar in all groups except
calcium antagonists. The serum levels of VEGF-C were not
correlated with the number of antihypertensive drugs used in
patients with CKD stage 5. CKD stage 5. We demonstrated that
serum VEGF-C levels decreased in the patients with CKD stage 3–4
and stage 5 and HD compared to healthy controls, and urinary
excretion of VEGF-C was increased in patients with CKD stage 3–4.Discussion
In this study, our results also demonstrated that the serum
levels of VEGF-C in patients with CKD stage 5 were not
correlated with the number of hypertensive drugs used.
A diet high in salt has been implicated in hypertension.
However, individual variations exist in the sensitivity of the BP
to salt and various mechanisms for salt-sensitive hypertension
[18]. The kidney is an organ that regulates total body sodium for
homeostasis of extracellular ﬂuid volume [19]. The extracellular
volume consists of two distinct body ﬂuid compartments, includ-
ing the interstitial and the intravascular spaces. Because
Kidney Res Clin Pract 32 (2013) 66–7170extracellular body ﬂuids are in equilibrium, excess interstitial
sodium is readily moved into the bloodstream for external renal
sodium excretion. It has been reported that lymphatic vessels
drain the interstitial ﬂuid [20]. Therefore, one of the critical
functions of lymphatic system is regulation of the interstitial ﬂuid
in sodium excessive state.
Machnik et al [5] demonstrated that leukocyte in the skin
interstitial space is involved in the development of hyperten-
sion. Mononuclear phagocyte cells such as macrophages par-
ticipated in the pathogenesis of hypertension. A diet high
in salt leads to interstitial hypertonic Na+ accumulation and
activation of TonEBP in mononuclear phagocyte cells in the
skin [4,5]. These authors suggested that TonEBP increases
VEGF-C production and increases lymphangiogenesis [6,7].
Therefore, VEGF-C can be associated with sodium excessive
state and activation of high TonEBP in high salt diet-induced
hypertension.
Because VEGF-C is involved in salt-induced hypertension and
hypertension in patients with CKD is linked to volume expansion,
we assumed that serum levels of VEGF-C increase in the patients
with hypertension and CKD. However, our data demonstrated
that serum levels of VEGF-C in patients with CKD stage 3–4 and
HD patients had signiﬁcantly lower levels of VEGF-C than control
patients. Therefore, the extra renal ﬂuid homeostasis mechanism
via the VEGF-C system in patients with CKD and hypertension
can be evaluated in the future.
There is a tendency that the mean level of serum VEGF-C
increased in stage 1 and stage 2 hypertension groups com-
pared with prehypertension in HD patients. However, the
differences did not reach statistical signiﬁcance. Because there
are various factors that can be involved in blood pressure
regulation in patients with end-stage kidney disease, we also
evaluated the relationship between the number of anti-
hypertensive drugs used and stage of hypertension. Our results
showed that there was no relationship between the number of
antihypertensive drugs used and stage of hypertension. There
may be many factors that can affect serum levels of VEGF-C in
normal patients or those with CKD. However, to our knowl-
edge, there are few reports about the regulating factors and
metabolism of serum VEGF-C. Therefore, further studies are
needed in this ﬁeld in the future.
Lely et al [14] demonstrated that serum levels of VEGF-C
increased in patients with preeclampsia. However, our results
demonstrated that blood levels of VEGF-C decreased in
patients with CKD stage 3–4 with hypertension. Also, our data
regarding serum VEGF-C level in patients with CKD were
different from those of patients with preeclampsia. We also
found that urinary excretion of VEGF-C was increased in
patients with CKD stage 3–4 compared with healthy control
patients. Thus, all of these data suggested that decreased
serum levels of VEGF-C may be associated with increased
excretion of VEGF-C in patients with CKD stage 3–4. To our
knowledge, these are the ﬁrst data in the English literature
about increased urinary excretion of VEGF-C in patients with
CKD. However, further investigation is needed regarding the
exact mechanism of VEGF-C kidney excretion.
There was evidence that increased serum levels of VEGF-C
are associated with cancer and cancer metastasis [21–25].
Thus, we evaluated the prevalence of cancer in each group.
Our demographic data showed that cancer prevalence in
patients with CKD stage 3–4 and HD patients was not different
compared with that in healthy control patients (Table 1).
Although healthy control patients in this study were youngerthan other patients, the prevalence of diabetes mellitus and
cerebrovascular disease was not different between groups. The
patients with CKD stage 3–4 tended to take more diuretics
compared with those in the healthy control group. However,
statistical signiﬁcance was not reached (P ¼ 0.08).
Recently, Slagman et al [15] demonstrated that VEGF-C
levels in patients with CKD and high salt intake are higher
than in patients with CKD and low salt intake. By comparison,
the serum levels of VEGF-C were low in our study of patients
with CKD stage 3 and 4. The difference in serum VEGF-C levels
between the study by Slagman et al and this study may be due
to the difference in kidney function: creatinine clearance in the
study by Slagman et al was 82 7 6 mL/min and eGFR in this
study was 16.1 mL/min/1.7m2.
The clinical signiﬁcance of this study was to develop the role of
VEGF-C in patients with hypertension and CKD. Our data demon-
strate that serum VEGF-C levels were decreased and urinary
VEGF-C excretion was increased in patients with CKD stage
3 and 4. Our results also showed that serum VEGF-C levels were
decreased in HD patients. We suggest that decreased serum VEGF-
C levels may be associated with increased urinary excretion of
VEGF-C. Furthermore, we suggest that the decreased serum levels
of VEGF-C may be associated with hypertension in patients with
CKD. However, we could not explain about the exact mechanism
of decreased serum VEGF-C level in HD patients.
The current study has several limitations. Patients with CKD
stages 3 and 4 and the normal control population are a
relatively small group. There were fundamental differences of
the three studied populations in age and the number of patients
using antihypertensive drugs. Thus, these ﬁndings should be
considered carefully in interpreting the results.
Our results demonstrate that circulating levels of VEGF-C
decreased in patients with CKD and the decreased circulating
VEGF-C levels may be associated with increased excretion of
VEGF-C in patients with CKD stage 3–4. Additional studies are
needed to evaluate the clinical relevance of the decreased
lymphangiogenic factor, VEGF-C, in patients with CKD.Conﬂict of interest
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